Rock Springs Capital

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Apollo Therapeutics is a biopharmaceutical company that focuses on translating groundbreaking medical research into viable therapeutics. Established as a collaborative venture among three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and leading pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation, Apollo Therapeutics aims to accelerate the development of innovative medicines sourced from top British academic research. The company specializes in developing pre-clinical and clinical-stage assets across various therapeutic areas, including oncology, major inflammatory disorders, and rare diseases. Apollo's team of experienced industry scientists works closely with academic institutions and industry partners to create tailored projects that enhance the likelihood of successful therapeutic delivery, ultimately aspiring to improve patient treatment outcomes and have a meaningful impact on healthcare.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

Apollo Therapeutics is a biopharmaceutical company that focuses on translating groundbreaking medical research into viable therapeutics. Established as a collaborative venture among three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and leading pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation, Apollo Therapeutics aims to accelerate the development of innovative medicines sourced from top British academic research. The company specializes in developing pre-clinical and clinical-stage assets across various therapeutic areas, including oncology, major inflammatory disorders, and rare diseases. Apollo's team of experienced industry scientists works closely with academic institutions and industry partners to create tailored projects that enhance the likelihood of successful therapeutic delivery, ultimately aspiring to improve patient treatment outcomes and have a meaningful impact on healthcare.

Spruce Biosciences, Inc. is a biopharmaceutical company based in Daly City, California, specializing in the development and commercialization of innovative therapies for rare endocrine disorders. Founded in 2014, the company is primarily focused on its lead product candidate, tildacerfont, which is undergoing clinical trials for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). Tildacerfont is being developed as a non-steroidal therapy aimed at improving disease management and reducing reliance on steroids for affected patients. Additionally, the company is exploring the use of tildacerfont for females with polycystic ovary syndrome. With a commitment to addressing the unmet medical needs of patients with rare endocrine conditions, Spruce Biosciences aims to enhance the quality of life for those who have been historically underserved by existing treatment options. The company also has a partnership with Eli Lilly and Company to explore further pharmaceutical applications of its compounds.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

AvengeBio is a biotechnology company based in Cambridge, Massachusetts, focused on developing cell-generated immunotherapies aimed at eradicating solid tumors. Founded in 2019, the company is advancing a drug delivery platform designed to enable the precision delivery of cytokines and other potent immunomodulatory molecules. This innovative approach allows for controlled release over time, fostering robust local and systemic anti-tumor immune responses while minimizing the toxicities typically associated with conventional immunotherapies. Through its research and development efforts, AvengeBio seeks to address the challenges posed by intractable solid tumors and improve treatment outcomes for cancer patients.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.

Apollo Therapeutics is a biopharmaceutical company that focuses on translating groundbreaking medical research into viable therapeutics. Established as a collaborative venture among three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and leading pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation, Apollo Therapeutics aims to accelerate the development of innovative medicines sourced from top British academic research. The company specializes in developing pre-clinical and clinical-stage assets across various therapeutic areas, including oncology, major inflammatory disorders, and rare diseases. Apollo's team of experienced industry scientists works closely with academic institutions and industry partners to create tailored projects that enhance the likelihood of successful therapeutic delivery, ultimately aspiring to improve patient treatment outcomes and have a meaningful impact on healthcare.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing innovative therapeutics for oncology and infectious diseases, with a particular emphasis on targeting dysfunctional lipid metabolism pathways. The company has a strong focus on fatty acid synthase (FASN) biology and has developed a pipeline of proprietary FASN inhibitors. Its lead product candidate, denifanstat, is an oral selective FASN inhibitor being investigated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, Sagimet is exploring antiviral therapeutic candidates aimed at treating respiratory syncytial virus, cytomegalovirus, and other human pathogens. Founded in 2006, Sagimet Biosciences was previously known as 3-V Biosciences, Inc. before rebranding in August 2019.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Biomea Fusion is a privately held biopharmaceutical company focused on developing precision medicines for cancer patients. The company targets specific gene alterations that drive tumor growth, aiming to create more effective therapies. Its lead program focuses on inhibiting the interaction between menin and the MLL complex, which is crucial in various tumors. Biomea Fusion's goal is to expedite the development process of these potentially groundbreaking medicines to deliver impactful treatments for patients with genetically defined cancers.

Immuneering Corporation is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York, New York. Founded in 2008, it specializes in genetic, genomic, and proteomic data analysis for pharmaceutical clients, aiming to enhance the clinical and commercial success of medicines. The company utilizes advanced techniques such as gene expression analysis, proteomics, and next-generation sequencing to uncover biological insights that inform drug development. Immuneering's expertise in translational bioinformatics is applied throughout the drug development process, particularly for oncologic and neurologic diseases, and is integral to its proprietary computational platform, known as Disease Cancelling Technology. This platform supports drug discovery initiatives and provides computational biology services to both pharmaceutical and biotechnology companies, contributing to the creation of therapies for serious illnesses, including cancer and autoimmune diseases.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Flame Biosciences is a clinical-stage biotechnology company based in New York, founded in 2017. The company specializes in developing innovative therapies for cancer and other inflammatory conditions. Its portfolio includes FL-101 therapy, designed to treat lung cancers driven by inflammation, and FL-201, aimed at reducing chronic inflammation in patients. Flame Biosciences is dedicated to improving the lives of individuals suffering from debilitating and life-threatening diseases through its transformative therapeutic approaches.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. Utilizing its proprietary Boltbody platform, the company creates immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with potent immune stimulants. This approach aims to transform cold tumors into immunologically active ones, enhancing the body’s ability to eliminate cancer. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, which is being developed as a monotherapy for patients with HER2-expressing solid tumors. With a strong emphasis on myeloid biology and cancer drug development, the company is dedicated to harnessing both innate and adaptive immune responses to improve cancer treatment outcomes. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics continues to push the boundaries of immuno-oncology.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Spruce Biosciences, Inc. is a biopharmaceutical company based in Daly City, California, specializing in the development and commercialization of innovative therapies for rare endocrine disorders. Founded in 2014, the company is primarily focused on its lead product candidate, tildacerfont, which is undergoing clinical trials for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). Tildacerfont is being developed as a non-steroidal therapy aimed at improving disease management and reducing reliance on steroids for affected patients. Additionally, the company is exploring the use of tildacerfont for females with polycystic ovary syndrome. With a commitment to addressing the unmet medical needs of patients with rare endocrine conditions, Spruce Biosciences aims to enhance the quality of life for those who have been historically underserved by existing treatment options. The company also has a partnership with Eli Lilly and Company to explore further pharmaceutical applications of its compounds.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

resTORbio, Inc., founded in 2016 and headquartered in Boston, Massachusetts, was a clinical-stage biopharmaceutical company focused on developing medicines to treat aging-related diseases. Its primary approach involved selectively inhibiting the target of rapamycin complex 1 (TORC1), a pathway linked to age-related decline in organ functions. The company's lead drug candidate, RTB101, an oral and potent TORC1 inhibitor, was being evaluated in Phase 1b/2a clinical trials for Parkinson's disease and other neurodegenerative diseases. Prior to its acquisition by Adicet Bio in September 2020, resTORbio collaborated with TrialSpark to investigate RTB-101 as a potential treatment for COVID-19.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Bristol-Myers Squibb, established in 1887, is a global biopharmaceutical company. It engages in the discovery, development, licensing, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio spans various therapeutic areas, with a significant focus on immuno-oncology. Key products include Opdivo and Yervoy for cancer indications, Eliquis for stroke prevention and blood clots, and Orencia for rheumatoid arthritis. Bristol-Myers Squibb collaborates with numerous partners to advance its pipeline and operates globally, with the U.S. contributing to approximately 70% of its total sales.

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, specializing in the development of immuno-oncology therapies. The company focuses on creating first-in-class agents that modulate the immune system to treat cancer and other diseases. Its lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor currently undergoing Phase Ib/2 clinical trials. Additionally, Corvus is developing CPI-006, an anti-CD73 monoclonal antibody in Phase I/Ib trials aimed at inhibiting adenosine production and stimulating immune cells, as well as a Phase I trial for COVID-19. Another candidate, CPI-818, is a small molecule inhibitor targeting interleukin-2-inducible T-cell kinase, also in Phase I/Ib trials. The company has established a strategic collaboration with Angel Pharmaceuticals to further advance its pipeline of investigational medicines. Founded in 2014, Corvus Pharmaceuticals aims to contribute significantly to the field of immunotherapy and improve patient outcomes in various diseases.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics aimed at treating cystic fibrosis (CF) and other genetic and degenerative disorders. The company specializes in discovering small molecule therapeutics that regulate the Proteostasis Network, which is essential for maintaining the balance of proteins in the body. Its lead product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis Therapeutics employs a theratyping approach to tailor treatments based on individual responses, regardless of specific CFTR mutations. The company has established collaboration agreements with organizations such as the Cystic Fibrosis Foundation to advance research and commercialization efforts for CF and other pulmonary diseases. Founded in 2006 and headquartered in Boston, Massachusetts, Proteostasis Therapeutics was previously known as Proteoguard, Inc. before rebranding in 2007.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of innovative antibody-based biopharmaceuticals. The company specializes in bispecific antibody therapeutics, utilizing its proprietary Oligoclonics technology to produce a unique class of human antibodies. This technology enables the generation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Merus is also advancing its full-length human multispecific antibody therapeutics, known as Biclonics. The company has a diverse pipeline of product candidates, including MCLA-128, MCLA-117, and MCLA-158, among others, all designed to address various challenges in immuno-oncology.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Cidara Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2012. It specializes in the discovery, development, and commercialization of innovative anti-infective therapies aimed at treating serious diseases. The company's lead product candidate, rezafungin acetate, is an echinocandin-class antifungal designed to address serious invasive fungal infections such as candidemia and invasive candidiasis, which are associated with high mortality rates. Additionally, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates for the prevention and treatment of various viral infections, including influenza, RSV, HIV, and coronaviruses. Through its unique therapeutic approaches, Cidara Therapeutics aims to enhance treatment paradigms and improve patient outcomes in the face of life-threatening illnesses.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing innovative therapeutics for oncology and infectious diseases, with a particular emphasis on targeting dysfunctional lipid metabolism pathways. The company has a strong focus on fatty acid synthase (FASN) biology and has developed a pipeline of proprietary FASN inhibitors. Its lead product candidate, denifanstat, is an oral selective FASN inhibitor being investigated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, Sagimet is exploring antiviral therapeutic candidates aimed at treating respiratory syncytial virus, cytomegalovirus, and other human pathogens. Founded in 2006, Sagimet Biosciences was previously known as 3-V Biosciences, Inc. before rebranding in August 2019.

Nivalis Therapeutics is a biotechnology company focused on developing innovative disease-modifying therapies aimed at cystic fibrosis (CF). The company is particularly dedicated to preserving intracellular S-nitrosoglutathione (GSNO), a naturally occurring molecule that plays a crucial role in cell signaling and is linked to the pathophysiology of CF. Its lead therapeutic candidate, N91115, specifically targets patients with the F508del mutation, which is the most prevalent mutation responsible for cystic fibrosis. Founded in 2007 and based in Boulder, Colorado, Nivalis Therapeutics aims to significantly improve the quality of life for individuals affected by cystic fibrosis and their families.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Spark Therapeutics, Inc. is a biotechnology company focused on developing gene therapy products aimed at treating debilitating genetic diseases. Headquartered in Philadelphia, Pennsylvania, the company was founded in 2013 and has established itself as a leader in the field of gene therapy, with a robust pipeline that includes LUXTURNA for retinal dystrophy, as well as several candidates for hemophilia and choroideremia. Spark is also exploring therapies for neurodegenerative diseases and inherited retinal diseases. The company holds a collaboration agreement with Pfizer for the development of hemophilia B treatments and has partnered with Novartis for the commercialization of its lead product outside the United States. Spark Therapeutics leverages a proprietary manufacturing platform and a team with extensive expertise in research, clinical development, and regulatory affairs, building on a legacy of innovation in gene therapy from its origins at The Children’s Hospital of Philadelphia. As of December 2019, Spark operates as a subsidiary of Roche Holding AG.